Neuracle, maker of the world's first approved invasive BCI, files for a Shanghai STAR Market IPO with RMB 2.5B target raise

Summary

Inside BCI reported that Neuracle Technology filed a prospectus for a Shanghai STAR Market IPO targeting RMB 2.5 billion in proceeds, following Chinese regulatory approval of its NEO invasive brain-computer interface implant for spinal cord injury. The listing would make Neuracle one of the first pure-play BCI companies to seek a public market valuation, signaling growing capital-market confidence in commercial invasive neurotechnology.